No additional prognostic value for MRE11 in squamous cell carcinomas of the anus treated with chemo-radiotherapy

Alexandra K. Walker, Christiana Kartsonaki, Elena Collantes, Judith Nicholson, Duncan C. Gilbert, Anne E. Kiltie*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)

Abstract

Background:The majority of anal cancers (84-95%) are driven by infection with human papillomavirus (HPV). HPV-positive tumours show significantly better responses to chemo-radiotherapy when compared with HPV-negative tumours. HPV infection is linked to alterations in DNA damage response proteins, including MRE11. MRE11 is a potential predictive biomarker for response to radiotherapy in muscle-invasive bladder cancer and may hold predictive power in other cancers.Methods:Using a previously reported cohort, we evaluated the levels of MRE11 in anal cancer and assessed its predictive value in this disease.Results:We found no association between the level of MRE11 and relapse-free survival following chemo-radiotherapy.Conclusions:MRE11 has no predictive value in the analysis of relapse-free survival after chemo-radiotherapy in anal cancer and does not add to the prognostic value of p16 and tumour-infiltrating lymphocyte scores. Further investigation into the role of DNA repair proteins in anal cancer is required.

Original languageEnglish
Pages (from-to)322-325
Number of pages4
JournalBritish Journal of Cancer
Volume117
Issue number3
DOIs
Publication statusPublished - 25 Jul 2017

Fingerprint Dive into the research topics of 'No additional prognostic value for MRE11 in squamous cell carcinomas of the anus treated with chemo-radiotherapy'. Together they form a unique fingerprint.

Cite this